Registrera dig | Logga in | FAQ      [?] 

Nature Reviews Drug Discovery

Articles from the last few issues of Nature Reviews Drug Discovery © Nature Publishing Group
  • Economic issues with follow-on protein products
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 733-737.
    by Michael Lanthier, Rachel Behrman, Clark Nardinelli
  • Informatics: New targets for old drugs
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 729-729.
    by Sarah Crunkhorn
    posted by 1 person reyez
  • Protein-Folding Diseases: Chaperones to the rescue
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 730-731.
    by Monica H Flight
  • Pharmacology: Flip to open
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 732-732.
    by Charlotte Harrison
  • Perspectives on NMR in drug discovery: a technique comes of age
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 738-745.
    by Maurizio Pellecchia, Ivano Bertini, David Cowburn, Claudio Dalvit, Ernest Giralt, Wolfgang Jahnke, Thomas L James, Steve W Homans, Horst Kessler, Claudio Luchinat, Bernd Meyer, Hartmut Oschkinat, Jeff Peng, Harald Schwalbe, Gregg Siegal
  • Nanoparticle therapeutics: an emerging treatment modality for cancer
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 771-782.
    by Mark E Davis, Zhuo ( Chen, Dong M Shin
  • Osteoporosis: overview and pipeline
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 725-726.
    by Uma Yasothan, Santwana Kar
  • Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 759-770.
    by György Haskó, Joel Linden, Bruce Cronstein, Pál Pacher
  • Targeting of tetraspanin proteins — potential benefits and strategies
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 747-758.
    by Martin E Hemler
  • 60 years studying heart-disease risk
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 715-715.
    by Daniel Levy
  • Alvimopan
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 727-728.
    by Conor P Delaney, Uma Yasothan, Peter Kirkpatrick
  • Aanticancer Drugs: Proteasome inhibitor unleashes three-pronged attack
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 730-731.
    by Alexandra Flemming
  • Anticancer drugs: Autophagy targeted in kidney cancer
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 731-731.
    by Bethan Hughes
  • Mixed results for disease-modification strategies for Alzheimer's disease
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 717-718.
    by Alisa Opar
  • Industry concern over EU hepatotoxicity guidance
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 719-719.
    by Bethan Hughes
  • Patent Watch
    Nature Reviews Drug Discovery, Vol. 7, No. 9., pp. 722-723.
    by Charlotte Harrison
  • Downsides to the nitrate–nitrite–nitric oxide pathway in physiology and therapeutics?
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 710-710.
    by Nirmal S Panesar
  • Downsides to the nitrate–nitrite–nitric oxide pathway in physiology and therapeutics? Reply from Lundberg, Weitzberg and Gladwin
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 710-710.
    by Jon O Lundberg, Eddie Weitzberg, Mark T Gladwin
  • The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 694-710.
    by David G Lambert
  • The molecular epidemiology of pain: a new discipline for drug discovery
    Nature Reviews Drug Discovery, Vol. 7, No. 8. (27 June 2008), pp. 647-658.
    by Mitchell B Max, Walter F Stewart
  • Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening
    Nature Reviews Drug Discovery, Vol. 7, No. 8. (18 July 2008), pp. 667-677.
    by Yusuf Tanrikulu, Gisbert Schneider
    posted by 1 person LamBras
  • The adult human brain in preclinical drug development
    Nature Reviews Drug Discovery, Vol. 7, No. 8. (11 July 2008), pp. 659-666.
    by Mike Dragunow
  • Trends in disease focus of drug development
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 639-640.
    by Johan PE Karlberg
  • Targeting bile-acid signalling for metabolic diseases
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 678-693.
    by Charles Thomas, Roberto Pellicciari, Mark Pruzanski, Johan Auwerx, Kristina Schoonjans
  • The future of pain
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 629-629.
    by Ronald Melzack
  • Stroke: Widening the therapeutic window?
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 643-643.
    by Sarah Crunkhorn
  • Cancer: New target for tumour immunotherapy
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 644-645.
    by Alexandra Flemming
  • Neurodegenerative diseases: Clearing up Aβ
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 644-645.
    by Charlotte Harrison
  • Stem cells: Overcoming barriers to iPS cells
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 645-645.
    by Bethan Hughes
  • Proteases: Novel route to protease targeting
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 646-646.
    by Monica H Flight
  • Pharma pursues novel models for academic collaboration
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 631-632.
    by Bethan Hughes
  • Patent Watch
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 636-637.
    by Charlotte Harrison
  • Certolizumab pegol
    Nature Reviews Drug Discovery, Vol. 7, No. 8., pp. 641-642.
    by Gil Y Melmed, Stephan R Targan, Uma Yasothan, Delphine Hanicq, Peter Kirkpatrick
  • ASCO presentations highlight value of cancer biomarkers
    Nature Reviews Drug Discovery, Vol. 7, No. 8. (11 July 2008), pp. 666-666.
    by Alisa Opar
  • Molecular imaging in drug development
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 591-607.
    by Jürgen K Willmann, Nicholas van Bruggen, Ludger M Dinkelborg, Sanjiv S Gambhir
    posted by 2 people monkare eugeneduff
  • Creating and evaluating genetic tests predictive of drug response
    Nature Reviews Drug Discovery, Vol. 7, No. 7. (20 June 2008), pp. 568-574.
    by Scott T Weiss, Howard L Mcleod, David A Flockhart, Eileen M Dolan, Neal L Benowitz, Julie A Johnson, Mark J Ratain, Kathleen M Giacomini
    posted by 1 person psique
  • The exploration of macrocycles for drug discovery — an underexploited structural class
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 608-624.
    by Edward M Driggers, Stephen P Hale, Jinbo Lee, Nicholas K Terrett
  • What drives success for specialty pharmaceuticals?
    Nature Reviews Drug Discovery, Vol. 7, No. 7. (06 June 2008), pp. 563-567.
    by Mark Gudiksen, Edd Fleming, Laura Furstenthal, Philip Ma
  • Novel agents in cystic fibrosis
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 555-556.
    by Shane Storey, Graeme Wald
  • Purinergic signalling and disorders of the central nervous system
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 575-590.
    by Geoffrey Burnstock
    posted by 1 person psique
  • Metabolic disease: Blocking brain enzyme curbs appetite
    Nature Reviews Drug Discovery, Vol. 7, No. 7. (20 June 2008), pp. 560-561.
    by Sarah Crunkhorn
  • Dabigatran etexilate
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 557-558.
    by Bengt I Eriksson, Helen Smith, Uma Yasothan, Peter Kirkpatrick
  • Monoclonal antibodies: Expanding the mAb pool
    Nature Reviews Drug Discovery, Vol. 7, No. 7. (20 June 2008), pp. 561-561.
    by Bethan Hughes
  • Leukaemia: Targeting silent cells
    Nature Reviews Drug Discovery, Vol. 7, No. 7. (20 June 2008), pp. 562-562.
    by Monica H Flight
  • Vaccines: Mast cells key to new vaccine adjuvants
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 560-561.
    by Alexandra Flemming
  • Eye diseases: Convenient leakage reduction
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 559-559.
    by Charlotte Harrison
  • Patent Watch
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 552-553.
    by Charlotte Harrison
  • ASCO presentations highlight value of cancer biomarkers
    Nature Reviews Drug Discovery, Vol. 7, No. 7., pp. 547-548.
    by Alisa Opar
  • Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time
    Nature Reviews Drug Discovery, Vol. 7, No. 6. (23 May 2008), pp. 530-540.
    by Keith A Wafford, Bjarke Ebert
    posted by 1 person reyez
  • Drug development of MET inhibitors: targeting oncogene addiction and expedience
    Nature Reviews Drug Discovery, Vol. 7, No. 6., pp. 504-516.
    by Paolo M Comoglio, Silvia Giordano, Livio Trusolino
    posted by 2 people reyez jyuh
    • Du kan hänvisa till den här sidan som: http://www.citeulike.org/journal/nature-reviews-drug-discovery

    Result page: 1 2 3 4 5 6 7 8 9 10 Next RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.